Remove tag cardiomyopathy
article thumbnail

Global (68M) cardiomyopathies market projected to grow to $9.63bn by 2031

Pharmaceutical Technology

In an expanded version of the sales forecast from GlobalData’s June 2022 publication, Cardiomyopathies: Global Drug Forecast and Market Analysis , the global cardiomyopathies market is expected to grow from $3.07bn last year to $9.63bn in 2031. of global cardiomyopathies sales in 2021 and 31.2%

Marketing 130
article thumbnail

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

The Pharma Data

First-quarter 2021 operational growth was primarily driven by: BNT162b2, which contributed $3.5 billion in global revenues; Eliquis globally, up 25% operationally, led by growth in the U.S., and Japan; Xeljanz globally, up 18% operationally, primarily driven by: 16% growth in the U.S., in December 2019; and. Amy Rose 212.733.7410. Source link.